The study suggests that GSTA3 plays a significant role in the effectiveness of immune checkpoint inhibitors in treating melanoma and implies the potential of GSTA3 as a genomic biomarker for predicting patient outcomes [64]. The gene discussed is GSTA3; the disease is melanoma.